Day: June 3, 2022

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2022 Jefferies Healthcare Conference on Friday, June 10, 2022 at 9:30 a.m. ET in NYC. A live webcast will be available in the investor section of the company’s website at www.beamtx.com, and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is...

Regulated informationIssy-les-Moulineaux, June 3, 2022 Monthly disclosure on share capital and voting rightsPursuant to Article L.233-8-II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorités des Marchés Financiers Registered name of the issuer: SODEXO255, quai de la Bataille de Stalingrad – 92130 ISSY-LES-MOULINEAUXDate Total number of shares Actual voting rights * Theoretical voting rights **May 31, 2022147,454,887216,308,406217,144,136* Actual voting rights: all of the Company shares have the same voting rights, except for treasury shares which do not have voting rights and registered shares held for more than four years, which have double voting rights.** Theoretical voting rights: the number of theoretical voting rights is calculated based on the shares having either single...

12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of life Tofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegeneration SOD1-ALS is a rare, progressive and fatal genetic form of the disease, leading to the loss of everyday functions and affecting approximately 2% of people with ALSCAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) — Biogen Inc. (NASDAQ: BIIB) today announced new 12-month data for tofersen, an investigational antisense drug for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The data show that earlier initiation of tofersen compared to delayed initiation (six months later in the open-label extension [OLE] study) slowed declines in clinical function,...

EVLI PLC MANAGERS TRANSACTIONS JUNE 3, 2022 AT 11.30 A.M. (EET/EEST) Evli Plc – Managers’ Transactions____________________________________________ Person subject to the notification requirementName: Sari HelanderPosition: Member of the Board/Deputy member Issuer: Evli PlcLEI: 984500F4CCF3AD74F766Notification type: INITIAL NOTIFICATIONReference number: 15826/5/4 ____________________________________________ Transaction date: 2022-06-01Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000513437Nature of the transaction: ACQUISITION Transaction details(1): Volume: 700 Unit price: 16.8 EURAggregated transactions(1): Volume: 700 Volume weighted average price: 16.8 EUREVLI PLCAdditional information:Mikaela Herrala, Head of Marketing, Communications and IR, Evli Plc, tel. +358 50 544 5740, mikaela.herrala@evli.comEvli...

Press release Malmö, Sweden, June 3, 2022   Acarix signs additional commercial agreement in US and receives rapid orders in both Mississippi and Tennessee Acarix today announces an additional commercial partnership in the US covering the states of Tennessee, Kentucky, Mississippi, and Alabama. The new partnership with Ancillary Care Services LLC has led to rapid orders and use of the CADScor®System by regional and rural clinics to enable accessible, rapid and cost-effective rule out of coronary artery disease. The US states of Tennessee, Kentucky, Mississippi, and Alabama have among the highest prevalence rates for heart disease in the country. Reasons include higher rates of obesity, type 2 diabetes and kidney disease, which are all risk factors for heart disease. “We are quickly gaining traction on the US market and signing agreements...

Bagsværd, Denmark, 3 June 2022 – Novo Nordisk today announced headline results from the main phases of ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) phase 3a trials with once-weekly insulin icodec. ONWARDS 1 (insulin naïve people with type 2 diabetes)ONWARDS 1 is a phase 3a, 78-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin glargine U100 (insulin glargine), both in combination with non-insulin anti-diabetic treatment, in 984 insulin-naïve people with type 2 diabetes. The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with insulin icodec compared to insulin glargine. From an overall baseline HbA1c of 8.5% once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of -1.55% compared to -1.35% for insulin glargine (estimated...

INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES Declaration pursuant to Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des marchés financiers (AMF)Date of settlementof information Total number of shares Number of shares without voting rights (*) Number of voting rights for threshold calculation (**) Number of actual voting rights (exercisable at shareholders’ meeting)May 31, 2022 22 421 332 2 042 132 25 018 983 22 976 851April 30, 2022 22 421 332 2 028 732 25 033 983 23 005 251March 31, 2022 22 421 332 1 915 712 24 894 051 22 978 339February 28, 2022 22 421 332 1 911 781 24 919 046 23 007 265January 31, 2022 22 421 332 1 881 298 24 937 775 23 056 477December 31, 2021 22 421 332 1 878 130 24 955 648 23 077 518(*) exclusively consisting of...

The Management board of AS Tallinna Vesi (hereinafter the Company) convened the Annual General Meeting of shareholders with the proposal for the resolutions set out below to be adopted by shareholders. The notice about convening the Annual General Meeting was published in the stock exchange information system and on the Company’s website on 11 May 2022 and in the daily newspaper Eesti Päevaleht on 12 May 2022. Votes were submitted by a total of 24 shareholders of the Company, whose votes represented 15,333,221 of the 20 million votes represented by shares of the Company, i.e. 76.67% of all votes represented by shares. On 03 June 2022, the shareholders of the Company adopted the following resolutions: Resolution no 1        To approve the consolidated 2021 Annual Report of the Company as submitted to the General Meeting.  The resolution...